Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.31 USD
+0.03 (2.34%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.30 -0.01 (-0.76%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Clearside Biomedical, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -32.49 | -32.95 | 0.38 | -18.21 | -30.77 |
Depreciation/Amortization & Depletion | 0.07 | 0.15 | 0.18 | 0.31 | 0.16 |
Net Change from Assets/Liabilities | 0.72 | 11.24 | -15.34 | 1.12 | -1.30 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 13.56 | 8.20 | 4.06 | 3.66 | 4.84 |
Net Cash From Operating Activities | -18.14 | -13.37 | -10.73 | -13.12 | -27.07 |
Property & Equipment | -1.78 | -0.25 | 0.00 | -0.06 | -0.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 32.95 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -1.78 | -0.25 | 0.00 | -0.06 | 32.93 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.10 | 0.13 | 11.58 | 0.26 | 0.05 |
Issuance (Repayment) of Debt | 1.67 | 0.57 | 12.21 | 7.61 | 5.32 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.35 | 30.64 | 0.00 | 0.00 | 3.32 |
Net Cash from Financing Activities | 0.41 | 31.33 | 23.78 | 7.87 | 8.70 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -19.50 | 17.72 | 13.05 | -5.31 | 14.55 |
Cash at Beginning of Period | 48.42 | 30.70 | 17.65 | 22.96 | 8.40 |
Cash at End of Period | 28.92 | 48.42 | 30.70 | 17.65 | 22.96 |
Diluted Net EPS | -0.53 | -0.55 | 0.01 | -0.39 | -0.81 |
Fiscal Year End for Clearside Biomedical, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -19.36 | -11.76 | -32.49 | -27.65 | -18.39 |
Depreciation/Amortization & Depletion | -0.04 | 0.03 | 0.07 | 0.05 | 0.03 |
Net Change from Assets/Liabilities | -0.64 | -1.08 | 0.72 | -1.28 | -0.76 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 6.51 | 4.96 | 13.56 | 10.26 | 6.56 |
Net Cash From Operating Activities | -13.53 | -7.85 | -18.14 | -18.63 | -12.56 |
Property & Equipment | -0.48 | -0.06 | -1.78 | -1.66 | -1.21 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -11.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -11.49 | -0.06 | -1.78 | -1.66 | -1.21 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 13.89 | 13.89 | 0.10 | 0.10 | 0.05 |
Issuance (Repayment) of Debt | 0.45 | 0.45 | 1.67 | 0.92 | 0.66 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -1.35 | -0.35 | -0.35 |
Net Cash from Financing Activities | 14.34 | 14.34 | 0.41 | 0.67 | 0.35 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -10.68 | 6.44 | -19.50 | -19.62 | -13.41 |
Cash at Beginning of Period | 28.92 | 28.92 | 48.42 | 48.42 | 48.42 |
Cash at End of Period | 18.24 | 35.36 | 28.92 | 28.80 | 35.01 |
Diluted Net EPS | -0.10 | -0.17 | -0.08 | -0.15 | -0.15 |